Maureen Cooper
Labcorp Oncology, Medical Affairs, Senior Director, Medical Science Liaison Team Lead
Maureen Cooper has a degree in Bioinformatics from the City University of New York and has spent over 15 years in the molecular diagnostics space. Her experience includes academic research at the University of Pittsburgh as well as industry where she has held multiple Commercial and Medical Affairs roles. Over the course of her career, Maureen has focused on educating Oncologists and Pathologists on the value of biomarker testing for cancer patients and building testing pathways for Oncology programs through education and collaboration.
Publications:
- August 23, 2024 Comprehensive Assessment of Immune Phenotype and Its Effects on Survival Outcomes in HER2-Low versus HER2-Zero Breast Cancer
- March 19, 2024 The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer
- October 30, 2024 Case report: Single gene testing and comprehensive genomic profiling in non-small cell lung cancer - a case series of divergent results from a large reference laboratory
- March 16, 2024 Testing for FRα in Ovarian Cancer: Why Testing the Primary Matters More Than the Metastasis
- February 12, 2024 Comprehensive Genomic Testing: Tissue Stewardship and Best Practices
- November 17, 2023 Genomic landscape of ERBB2 alterations in solid tumors without an approved HER2-targeted therapy